167 related articles for article (PubMed ID: 37963308)
1. Correlations among Core Outcomes in Menopause-recommended vasomotor symptom outcomes in MsFLASH trials.
Carpenter JS; Larson JC; Hunter MS; Lensen S; Chen CX; Guthrie KA
Menopause; 2024 Jan; 31(1):3-9. PubMed ID: 37963308
[TBL] [Abstract][Full Text] [Related]
2. Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Guthrie KA; Larson JC; Ensrud KE; Anderson GL; Carpenter JS; Freeman EW; Joffe H; LaCroix AZ; Manson JE; Morin CM; Newton KM; Otte J; Reed SD; McCurry SM
Sleep; 2018 Jan; 41(1):. PubMed ID: 29165623
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial.
Cohen LS; Joffe H; Guthrie KA; Ensrud KE; Freeman M; Carpenter JS; Learman LA; Newton KM; Reed SD; Manson JE; Sternfeld B; Caan B; Freeman EW; LaCroix AZ; Tinker LF; Booth-Laforce C; Larson JC; Anderson GL
Menopause; 2014 Apr; 21(4):347-54. PubMed ID: 23982113
[TBL] [Abstract][Full Text] [Related]
4. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.
Joffe H; Guthrie KA; Larson J; Cohen LS; Carpenter JS; Lacroix AZ; Freeman EW
Menopause; 2013 Mar; 20(3):261-8. PubMed ID: 23435022
[TBL] [Abstract][Full Text] [Related]
5. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.
Joffe H; Guthrie KA; LaCroix AZ; Reed SD; Ensrud KE; Manson JE; Newton KM; Freeman EW; Anderson GL; Larson JC; Hunt J; Shifren J; Rexrode KM; Caan B; Sternfeld B; Carpenter JS; Cohen L
JAMA Intern Med; 2014 Jul; 174(7):1058-66. PubMed ID: 24861828
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of exercise for menopausal symptoms: a randomized controlled trial.
Sternfeld B; Guthrie KA; Ensrud KE; LaCroix AZ; Larson JC; Dunn AL; Anderson GL; Seguin RA; Carpenter JS; Newton KM; Reed SD; Freeman EW; Cohen LS; Joffe H; Roberts M; Caan BJ
Menopause; 2014 Apr; 21(4):330-8. PubMed ID: 23899828
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of yoga for vasomotor symptoms: a randomized controlled trial.
Newton KM; Reed SD; Guthrie KA; Sherman KJ; Booth-LaForce C; Caan B; Sternfeld B; Carpenter JS; Learman LA; Freeman EW; Cohen LS; Joffe H; Anderson GL; Larson JC; Hunt JR; Ensrud KE; LaCroix AZ
Menopause; 2014 Apr; 21(4):339-46. PubMed ID: 24045673
[TBL] [Abstract][Full Text] [Related]
8. Symptom clusters among MsFLASH clinical trial participants.
Woods NF; Hohensee C; Carpenter JS; Cohen L; Ensrud K; Freeman EW; Guthrie KA; Joffe H; LaCroix AZ; Otte JL
Menopause; 2016 Feb; 23(2):158-65. PubMed ID: 26506500
[TBL] [Abstract][Full Text] [Related]
9. Results of a pilot study of a cooling mattress pad to reduce vasomotor symptoms and improve sleep.
Avis NE; Levine BJ; Coeytaux R
Menopause; 2022 Aug; 29(8):973-978. PubMed ID: 35881974
[TBL] [Abstract][Full Text] [Related]
10. A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative.
Lensen S; Archer D; Bell RJ; Carpenter JS; Christmas M; Davis SR; Giblin K; Goldstein SR; Hillard T; Hunter MS; Iliodromiti S; Jaisamrarn U; Joffe H; Khandelwal S; Kiesel L; Kim BV; Lambalk CB; Lumsden MA; Maki PM; Nappi RE; Panay N; Roberts H; Shifren J; Simon JA; Vincent A; Wolfman W; Hickey M
Menopause; 2021 Apr; 28(8):852-858. PubMed ID: 33906204
[TBL] [Abstract][Full Text] [Related]
11. Assessment of women's treatment preferences for vasomotor symptoms due to menopause.
Shiozawa A; Thurston RC; Cook E; Yang H; King DD; Kristy RM; Mancuso S
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1117-1128. PubMed ID: 37650213
[TBL] [Abstract][Full Text] [Related]
12. Effects of bothersome symptoms during the late reproductive stage and menopausal transition: observations from the Women Living Better Survey.
Woods NF; Coslov N; Richardson MK
Menopause; 2023 Jan; 30(1):45-55. PubMed ID: 36576442
[TBL] [Abstract][Full Text] [Related]
13. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
[TBL] [Abstract][Full Text] [Related]
14. A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep.
Joffe H; Crawford S; Economou N; Kim S; Regan S; Hall JE; White D
Sleep; 2013 Dec; 36(12):1977-85. PubMed ID: 24293774
[TBL] [Abstract][Full Text] [Related]
15. MsFLASH participants' priorities for alleviating menopausal symptoms.
Carpenter JS; Woods NF; Otte JL; Guthrie KA; Hohensee C; Newton KM; Joffe H; Cohen L; Sternfeld B; Lau RJ; Reed SD; LaCroix AZ
Climacteric; 2015; 18(6):859-66. PubMed ID: 26517583
[TBL] [Abstract][Full Text] [Related]
16. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
[TBL] [Abstract][Full Text] [Related]
17. Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).
Nappi RE; Johnson KA; Stute P; Blogg M; English M; Morga A; Scrine L; Siddiqui E; Ottery FD
Menopause; 2024 Jun; 31(6):512-521. PubMed ID: 38626380
[TBL] [Abstract][Full Text] [Related]
18. Estimation of placebo effect in randomized placebo-controlled trials for moderate or severe vasomotor symptoms: a meta-analysis.
Zhou T
Menopause; 2023 Jan; 30(1):5-10. PubMed ID: 36576440
[TBL] [Abstract][Full Text] [Related]
19. Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters.
Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Komm BS
Menopause; 2016 Oct; 23(10):1060-6. PubMed ID: 27404028
[TBL] [Abstract][Full Text] [Related]
20. Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis.
Chavez MP; Pasqualotto E; Ferreira ROM; Hohl A; de Moraes FCA; Schmidt PHS; Rodrigues ALSO; de Sa JR
Climacteric; 2024 Jun; 27(3):245-254. PubMed ID: 38619017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
